<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02597439</url>
  </required_header>
  <id_info>
    <org_study_id>ABR54654</org_study_id>
    <secondary_id>2015-003503-39</secondary_id>
    <nct_id>NCT02597439</nct_id>
  </id_info>
  <brief_title>Placebo-controlled Trial in Subjects at Ultra-high Risk for Psychosis With Omega-3 Fatty Acids in Europe</brief_title>
  <acronym>PURPOSE</acronym>
  <official_title>Placebo-controlled Trial in Subjects at Ultra-high Risk for Psychosis With Omega-3 Fatty Acids in Europe</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rene Kahn</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>UMC Utrecht</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether omega-3 fatty acids are effective in the&#xD;
      prevention of psychosis in individuals at ultra-high risk for psychosis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PURPOSE is a randomized double-blind placebo-controlled study. Main objective is to assess&#xD;
      the effectivity of omega-3 fatty acid treatment in the prevention of psychosis. The primary&#xD;
      outcome measure is the rate of transition to psychosis as determined through CAARMS. Subjects&#xD;
      in the age range of 13-20 years with a higher chance of developing psychosis, as determined&#xD;
      by the CAARMS, are treated for 6 months with omega-3 fatty acids or placebo. This study in&#xD;
      conducted at 14 sites in 9 countries.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">September 30, 2016</start_date>
  <completion_date type="Anticipated">January 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">January 31, 2023</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Transition rate</measure>
    <time_frame>2 years</time_frame>
    <description>To compare transition rates to psychosis during 2 years of follow-up between the omega-3 fatty acids arm and the placebo arm. Starting point is the first administration of medication at the end of visit 2. Endpoint is the moment that a UHR subject makes a transition to psychosis according to the CAARMS criteria.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Discontinuation rate</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symptomatology</measure>
    <time_frame>2 years</time_frame>
    <description>Symptomatology will be examined with the CAARMS.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Psychosocial functioning</measure>
    <time_frame>2 years</time_frame>
    <description>As determined by the Social and Occupational Functioning Assessment Scale (SOFAS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cognitive function</measure>
    <time_frame>2 years</time_frame>
    <description>Cognitive function is determined by the WAIS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MRI measures</measure>
    <time_frame>2 years</time_frame>
    <description>Brain structure and function are measured in three MRI sessions, consisting of structural MRI, resting state functional MRI, Diffusion Tensor Imaging (DTI), and functional MRI during reward processing.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood levels of bioactive lipids</measure>
    <time_frame>2 years</time_frame>
    <description>Assessment of the omega-3 to omega-6 ratio</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tolerability associated with omega-3 fatty acid treatment</measure>
    <time_frame>2 years</time_frame>
    <description>Number of participants with treatment-related adverse events as assessed by the physician.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood levels of (epi)genetic markers</measure>
    <time_frame>2 years</time_frame>
    <description>Epigenetic markers of interest include but are not restricted to GAD1 and RELN, which are genes coding for the proteins GAD67 and reelin, respectively.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood levels of immune parameters</measure>
    <time_frame>2 years</time_frame>
    <description>Immune parameters that are assessed include but are not restricted to interferon-γ, interleukin (IL)-1α, IL-1RA, IL-5, IL-10, IL12p40, IL-15, IL-18 and tumour necrosis factor-α.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Positive and negative symptoms</measure>
    <time_frame>2 years</time_frame>
    <description>Symptomatology will be examined with the Positive and Negative Syndrome Scale (PANSS).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Level of functioning</measure>
    <time_frame>2 years</time_frame>
    <description>Symptomatology will be examined with the Global Assessment of Functioning scale (GAF).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Impression</measure>
    <time_frame>2 years</time_frame>
    <description>Symptomatology will be examined with the Clinical Global Impression Scale (CGI).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Level of depression</measure>
    <time_frame>2 years</time_frame>
    <description>Symptomatology will be examined with the Beck's Depression Inventory (BDI).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Role functioning</measure>
    <time_frame>2 years</time_frame>
    <description>Determined by the Global Functioning Role (GF:R) scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Social functioning</measure>
    <time_frame>2 years</time_frame>
    <description>Determined by the Global Functioning Social (GF:S) scale.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">145</enrollment>
  <condition>Ultra High Risk for Psychosis</condition>
  <arm_group>
    <arm_group_label>Omega-3 fatty acids</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects will be treated daily with 1.2 gram omega-3 polyunsaturated fatty acids (720 mg eicosapentaenoic acid (EPA) and 480 mg Docosahexaenoic acid(DHA)) for six months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects will be treated daily with placebo for six months. Placebo capsules will contain a 1:1 combination of coconut oil and medium chain triglycerides because these do not contain polyunsaturated fatty acids and have no impact on omega-3 fatty acid metabolism. Placebo capsules also contain the same amount of vitamin E as the omega-3 capsules and 1% fish oil to mimic flavour and taste.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Omega-3 fatty acids</intervention_name>
    <arm_group_label>Omega-3 fatty acids</arm_group_label>
    <other_name>Fishoil</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Written informed consent of the subject. For individuals younger than 18 years of age&#xD;
             the parents / legal representatives need to give consent, and the subject can provide&#xD;
             assent (whether the latter is required depends on local laws and regulations).&#xD;
&#xD;
          -  UHR diagnosis as made using the Comprehensive Assessment of At-Risk Mental States&#xD;
             (CAARMS) (Yung et al., 2005). Subjects have to meet one or more of the following&#xD;
             criteria: (a) attenuated psychotic symptoms, (b) brief limited intermittent psychotic&#xD;
             symptoms (a history of one or more episodes of frank psychotic symptoms that resolved&#xD;
             spontaneously within 1 week in the past year), or (c) either the presence of&#xD;
             schizotypal personality disorder or a family history of psychosis in a first-degree&#xD;
             relative, all three together with a recent decline in function.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any clinically significant medical condition that may influence the results of the&#xD;
             trial or affect the ability to take part in a trial.&#xD;
&#xD;
          -  Laboratory screening values considered clinically relevant by a medical doctor for&#xD;
             transaminases, thyroid hormones or coagulation parameters&#xD;
&#xD;
          -  Current or past DSM-IV diagnosis of psychosis, as measured with K-SADS-PL&#xD;
&#xD;
          -  Current treatment with an antipsychotic or mood-stabilising agent&#xD;
&#xD;
          -  Intake of an antipsychotic or mood-stabilising agent in the two weeks prior to study&#xD;
             inclusion&#xD;
&#xD;
          -  Intake of an antipsychotic agent equivalent to a total haloperidol use of &gt;50 mg in&#xD;
             the six months prior to study inclusion&#xD;
&#xD;
          -  A first-degree relative (i.e. parents, offspring or siblings) participating in this&#xD;
             study&#xD;
&#xD;
          -  UHR diagnosis on the basis of attenuated psychotic symptoms that are entirely&#xD;
             explained by acute intoxication&#xD;
&#xD;
          -  Current aggression or dangerous behaviour (PANSS G14 score 5 or above)&#xD;
&#xD;
          -  Current suicidality / self-harm (PANSS G6 score 7)&#xD;
&#xD;
          -  Current DSM-IV diagnosis of alcohol or substance dependence as measured with K-SADS-PL&#xD;
&#xD;
          -  Any current or previous neurological disorder, including epilepsy&#xD;
&#xD;
          -  History of head injury resulting in unconsciousness lasting at least 1 hour&#xD;
&#xD;
          -  IQ &lt; 70&#xD;
&#xD;
          -  More than 4 weeks of regular omega-3 supplementation (&gt;2 daily capsules standard&#xD;
             strength providing &gt;600 mg combined EPA/DHA) within the last 6 months.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>13 Years</minimum_age>
    <maximum_age>20 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>René Kahn, Prof. dr.</last_name>
    <role>Study Chair</role>
    <affiliation>UMC Utrecht</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>BioPsyC Biopsychosocial Corporation</name>
      <address>
        <city>Vienna</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Child and Adolescent Psychiatry, University of Tübingen</name>
      <address>
        <city>Tübingen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Schneider Children's Medical Center</name>
      <address>
        <city>Petach Tikva</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tel Hashomer The Sheba Medical Center</name>
      <address>
        <city>Ramat Gan</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fondazione Santa Lucia</name>
      <address>
        <city>Rome</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sapienza University of Rome</name>
      <address>
        <city>Rome</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brain Center Rudolf Magnus, Department of Psychiatry, University Medical Center Utrecht</name>
      <address>
        <city>Utrecht</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute of Clinical Medicine, University of Bergen</name>
      <address>
        <city>Bergen</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Infantil Passeig Sant Joan de Deu</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario Gregorio Marañon</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Idival, University of Cantabria, Cibersam Unidad de investigacion en psiquiatria</name>
      <address>
        <city>Santander</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ZKJP University Zürich</name>
      <address>
        <city>Zurich</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Psychiatry, Centre for Clinical Brain Sciences</name>
      <address>
        <city>Edinburgh</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Germany</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Norway</country>
    <country>Spain</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>October 15, 2015</study_first_submitted>
  <study_first_submitted_qc>November 3, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 5, 2015</study_first_posted>
  <last_update_submitted>February 8, 2021</last_update_submitted>
  <last_update_submitted_qc>February 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>UMC Utrecht</investigator_affiliation>
    <investigator_full_name>Rene Kahn</investigator_full_name>
    <investigator_title>Prof. dr.</investigator_title>
  </responsible_party>
  <keyword>Ultra-high risk</keyword>
  <keyword>UHR</keyword>
  <keyword>psychosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psychotic Disorders</mesh_term>
    <mesh_term>Mental Disorders</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

